Allogene Therapeutics ALLO Change in Other Liabilities
Change in Other Liabilities at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's change in other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's change in other liabilities?
- Allogene Therapeutics (ALLO) reported change in other liabilities of $316K in Q1 2026.
- How has Allogene Therapeutics's change in other liabilities changed year-over-year?
- Allogene Therapeutics's change in other liabilities increased by 92.7% year-over-year, from $164K to $316K.
- What is the long-term trend for Allogene Therapeutics's change in other liabilities?
- Over 2 years (2022 to 2025), Allogene Therapeutics's change in other liabilities has grown at a -22.3% compound annual growth rate (CAGR), from -$1.88M to $1.14M.
- What does change in other liabilities mean?
- Change in miscellaneous liabilities affecting operating cash flow.